H-Leu-Ser-Lys-Leu-OH

H-Leu-Ser-Lys-Leu-OH (LSYL) is a latency-associated peptide at the amino terminus of LAP, with inhibitory effect on TGF-β1 activation. H-Leu-Ser-Lys-Leu-OH, binding with KRFK (HY-P3970), can block the signal transduction of TGF-β1, and prevent the progression of hepatic damage and fibrosis[1].

Product Specifications

CAS Number

[162559-45-7]

UNSPSC

12352209

Target

TGF-beta/Smad

Type

Peptides

Related Pathways

Stem Cell/Wnt; TGF-beta/Smad

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/h-leu-ser-lys-leu-oh.html

Solubility

10 mM in DMSO

Smiles

CC(C)C[C@@H](C(O)=O)NC([C@H](CCCCN)NC([C@H](CO)NC([C@H](CC(C)C)N)=O)=O)=O

Molecular Formula

C21H41N5O6

Molecular Weight

459.58

References & Citations

[1]Kondou H, et al. A blocking peptide for transforming growth factor-beta1 activation prevents hepatic fibrosis in vivo. J Hepatol. 2003 Nov;39 (5) :742-8.